Consulta: subjectFacets:"High-dose cytarabine"
Registros recuperados: 1
Data/hora: 10/06/2024 09:57:09

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
Provedor de dados: 56
Autores: Azevedo,M.C.; Velloso,E.D.R.P.; Buccheri,V.; Chamone,D.A.F.; Dorlhiac-Llacer,P.E.
In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of cytarabine that patients received for consolidation therapy and divided them into 3 groups according to dose. We conducted a single-center, retrospective study involving 311 non-promyelocytic AML patients with a median age of 36 years (16-79 years) who received curative treatment between 1978 and 2007. The 131 patients who received cytarabine consolidation were assigned to study groups by their cytarabine dose protocol. Group 1 (n=69) received &lt;1.5 g/m2 every 12 h on 3...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Acute myeloid leukemia; Chemotherapy; Consolidation therapy; High-dose cytarabine; Prognosis.
Ano: 2015
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000200178